Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.034
Buy
RSI(14)
53.093
Neutral
STOCH(KDJ)(9,3,3)
54.190
Neutral
ATR(14)
0.641
Low Volatility
CCI(14)
41.501
Neutral
Williams %R
45.455
Neutral
TRIX(12,20)
0.098
Sell
StochRSI(14)
56.924
Sell
Design Therapeutics Inc
DSGN10.530USD
-0.180-1.68%
Close 03/27, 16:00（ET）Quotes delayed by 15 min
566.70MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Design Therapeutics Inc
Currency: USD Updated: 2026-03-27Key Insights
Design Therapeutics Inc's fundamentals are relatively weak, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 149 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 14.67.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Design Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Design Therapeutics Inc Highlights
StrengthsRisks
Design Therapeutics, Inc. is a biotechnology company. It is engaged in the research and development of GeneTACT molecules, which are small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its Friedreich ataxia (FA) program is focused on the development of a disease-modifying treatment. Its DT-216 is developed to overcome the FXN transcription impairment that causes FA. DT-216 is in Phase I clinical trial. It is also engaged in developing DT-216 to enable higher exposure and chronic administration for treatment of FA, known as DT-216P2, which uses the same drug substance, DT-216. Its FECD program is focused on the development of a potentially disease-modifying medical treatment for FECD, DT-168, which is in Phase I clinical trial. Its Huntington's Disease program is focused on the development of a potentially disease-modifying treatment for HD.
Undervalued
The company’s latest PE is -8.65, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 33.55M shares, decreasing 3.29% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 287.10K shares of this stock.
Analyst Rating
Based on
6
analysts
Strong Buy
Current Rating
14.667
Target Price
+36.94%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-03-27The current financial score of Design Therapeutics Inc is 5.46, ranking 360 out of 391 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low.
Score
Financials
2.04
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.50
Operational Efficiency
4.00
Growth Potential
6.75
Shareholder Returns
7.03
Design Therapeutics Inc's Company Valuation
Currency: USD Updated: 2026-03-27The current valuation score of Design Therapeutics Inc is 6.81, ranking 214 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is -8.65, which is -82.22% below the recent high of -1.54 and -6.84% above the recent low of -9.24.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 149/391
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-03-27The current earnings forecast score of Design Therapeutics Inc is 8.00, ranking 163 out of 391 in the Biotechnology & Medical Research industry. The average price target is 12.50, with a high of 15.00 and a low of 7.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
6
analysts
Strong Buy
Current Rating
14.667
Target Price
+36.94%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
548
Total
6
Median
6
Average
Company name
Ratings
Analysts
Design Therapeutics Inc
DSGN
6
CRISPR Therapeutics AG
CRSP
29
IQVIA Holdings Inc
IQV
27
argenx SE
ARGX
26
Intellia Therapeutics Inc
NTLA
24
Beigene Ltd
ONC
24
1
2
3
...
110
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-03-27The current price momentum score of Design Therapeutics Inc is 7.31, ranking 56 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 11.28 and the support level at 9.74, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
10.490
Buy
MA10
10.535
Sell
MA20
10.330
Buy
MA50
10.253
Buy
MA100
9.512
Buy
MA200
7.336
Buy
Institutional Confidence
Currency: USD Updated: 2026-03-27The current institutional shareholding score of Design Therapeutics Inc is 5.00, ranking 136 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 67.46%, representing a quarter-over-quarter decrease of 10.75%. The largest institutional shareholder is Steven Cohen, holding a total of 5.37M shares, representing 8.71% of shares outstanding, with 172.02% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Ansari (Aseem Z. Ph.D.)
SR One Capital Management, LP
Quan Venture Fund II LP
Light Irrevocable Trust.
Star Irrevocable Trust.
Logos Global Management LP
Baker Bros. Advisors LP
BlackRock Institutional Trust Company, N.A.
1
2
Risk Assessment
Currency: USD Updated: 2026-03-27The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. No risk assessment score is currently available for Design Therapeutics Inc. The Biotechnology & Medical Research industry's average is 3.38. The company's beta value is 1.59. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. Design Therapeutics Inc’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.
Score
Beta vs S&P 500 index
1.57
VaR
+7.59%
240-Day Maximum Drawdown
+33.85%
240-Day Volatility
+84.71%
Return
Best Daily Return
60 days
+11.90%
120 days
+21.64%
5 years
+28.49%
Worst Daily Return
60 days
-6.99%
120 days
-8.05%
5 years
-70.46%
Sharpe Ratio
60 days
+0.80
120 days
+2.00
5 years
+0.26
Risk Assessment
Maximum Drawdown
240 days
+33.85%
3 years
+75.55%
5 years
+92.80%
Return-to-Drawdown Ratio
240 days
+7.81
3 years
+0.26
5 years
-0.13
Skewness
240 days
+0.29
3 years
-2.42
5 years
-1.75
Volatility
Realised Volatility
240 days
+84.71%
5 years
+98.52%
Standardised True Range
240 days
+4.74%
5 years
+6.77%
Downside Risk-Adjusted Return
120 days
+420.67%
240 days
+420.67%
Maximum Daily Upside Volatility
60 days
+48.27%
Maximum Daily Downside Volatility
60 days
+44.21%
Liquidity
Average Turnover Rate
60 days
+0.20%
120 days
+0.21%
5 years
--
Turnover Deviation
20 days
-30.29%
60 days
-49.29%
120 days
-48.44%
Peer Comparison
Biotechnology & Medical Research
Design Therapeutics Inc
DSGN
5.95 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.42 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Madrigal Pharmaceuticals Inc
MDGL
8.27 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.27 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Day One Biopharmaceuticals Inc
DAWN
8.26 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.21 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
